Company Performance Metrics
- Jin Chen: Senior VP / Global Head, DMPK and Clinical Pharmacology
- Steven E. Linberg: Chief Product Development Officer & MDPast Role: Airway Therapeutics, Team Member
HighTide Therapeutics is a global clinical-stage biopharmaceutical company focused on discovering and developing novel drugs to treat chronic liver diseases, gastrointestinal diseases and metabolic disorders with high unmet needs. The company integrates expertise in disease biology, medicinal chemistry, clinical development and regulatory affairs
to advance its growing pipeline of drugs.
The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The FDA has granted HTD1801 Fast Track Designation in both diseases.
HighTide Therapeutics was established in 2011 by Liping Liu in Shenzhen, Guangdong.
